And while you may feel scared or overwhelmed, it's important to remember that you are not alone. The TAFINLAR + MEKINIST team is committed to providing those affected by "BRAF+" melanoma with valuable information and support. We may occasionally post links to informative third-party websites that are intended to help you throughout treatment. Novartis Pharmaceuticals Corporation does not control and is not responsible for the content of these third-party websites. APPROVED USES
TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:
• that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and
• that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene
TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery. TAFINLAR, in combination with MEKINIST, is not for use in treating people with wild-type "BRAF" melanoma. MEKINIST should not be used to treat people who already have received a "BRAF" inhibitor for treatment of their melanoma and it did not work or is no longer working. Your health care provider will perform a test to make sure that TAFINLAR and MEKINIST in combination is right for you. It is not known if TAFINLAR, in combination with MEKINIST, is safe and effective in children younger than 1 year of age. It is not known if TAFINLAR used alone is safe and effective in children.
